KR930005972A - N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민 - Google Patents

N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민 Download PDF

Info

Publication number
KR930005972A
KR930005972A KR1019920017511A KR920017511A KR930005972A KR 930005972 A KR930005972 A KR 930005972A KR 1019920017511 A KR1019920017511 A KR 1019920017511A KR 920017511 A KR920017511 A KR 920017511A KR 930005972 A KR930005972 A KR 930005972A
Authority
KR
South Korea
Prior art keywords
phenyl
alkyl
propylamine
pharmaceutically acceptable
alkylthiophenoxy
Prior art date
Application number
KR1019920017511A
Other languages
English (en)
Other versions
KR100221180B1 (ko
Inventor
리챠드 게러트 도날드
웨인 로버트슨 데이비드
타이와이 윙 데이비드
Original Assignee
원본미기재
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 일라이 릴리 앤드 캄파니 filed Critical 원본미기재
Publication of KR930005972A publication Critical patent/KR930005972A/ko
Application granted granted Critical
Publication of KR100221180B1 publication Critical patent/KR100221180B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/29—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 노르에피네프린 실조와 관련된 신경학적 질환을 치료하기 유용한 N-알킬-3-페닐-3-(2-치환된 페녹시)프로필아민을 제공한다.

Description

N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 하기 일반식(Ⅰ)의 화합물 또는 그의 약학적으로 허용가능한 산 부가염:
    상기식에서, X는 C1내지 C4알킬티오이고, Y는 C1내지 C2알킬이다.
  2. N-메틸-3-페닐-3-(2-메틸티오페녹시)프로필아민 또는 그의 약학적으로 허용가능한 산 부가염.
  3. 제1항 또는 제2항에 청구된 바와 같은 화합물 또는 그의 약학적으로 허용가능한 산 부가염을 하나 이상의 약학적으로 허용가능한 담체, 희석제 또는 부형제와 함께 포함하는 약학적 제형.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920017511A 1991-09-27 1992-09-25 N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민 KR100221180B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/766,993 US5281624A (en) 1991-09-27 1991-09-27 N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US766,993 1991-09-27

Publications (2)

Publication Number Publication Date
KR930005972A true KR930005972A (ko) 1993-04-20
KR100221180B1 KR100221180B1 (ko) 1999-09-15

Family

ID=25078150

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920017511A KR100221180B1 (ko) 1991-09-27 1992-09-25 N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민

Country Status (23)

Country Link
US (1) US5281624A (ko)
EP (1) EP0534756A3 (ko)
JP (2) JP3256291B2 (ko)
KR (1) KR100221180B1 (ko)
CN (1) CN1033580C (ko)
AT (1) ATE124934T1 (ko)
AU (1) AU655075B2 (ko)
BR (2) BR9203743A (ko)
CA (2) CA2079162A1 (ko)
CZ (1) CZ281817B6 (ko)
DE (1) DE69203424T2 (ko)
FI (1) FI111250B (ko)
HU (1) HU215519B (ko)
IL (1) IL103277A (ko)
MX (1) MX9205433A (ko)
MY (1) MY108304A (ko)
NO (1) NO178109C (ko)
NZ (1) NZ244460A (ko)
RU (1) RU2057120C1 (ko)
SK (1) SK280480B6 (ko)
TW (1) TW249225B (ko)
YU (1) YU87192A (ko)
ZA (1) ZA927240B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
CA2227410A1 (en) * 1995-07-24 1997-02-06 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
EP1069900B1 (en) * 1998-04-09 2005-08-10 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of neuropsychiatric disorders
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
CZ20013607A3 (cs) * 1999-04-06 2002-06-12 Sepracor Inc. Farmaceutický prostředek
DE60022504T2 (de) * 1999-05-24 2006-06-29 Mitsubishi Pharma Corp. Phenoxypropylamin-derivate
PT1459751E (pt) * 1999-07-01 2005-11-30 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para tratar as enxaquecas
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
ES2287338T3 (es) * 2001-11-30 2007-12-16 Eli Lilly And Company Uso de inhibidores de recaptacion de norepinefrina para el tratamiento de trastornos de tics.
HUP0402619A3 (en) * 2001-12-11 2008-04-28 Lilly Co Eli Use of norepinephrine reuptake inhibitors for the preparation of a medicament for treatment of cognitive failure
US6846823B2 (en) * 2003-04-04 2005-01-25 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
CA2548304A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
ITMI20061987A1 (it) * 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
WO2019076904A1 (en) * 2017-10-16 2019-04-25 Esteve Pharmaceuticals, S.A. PROPANAMINE DERIVATIVES FOR THE TREATMENT OF PAIN AND PAIN DISEASES ASSOCIATED WITH PAIN
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4313896A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Aryloxyphenylpropylamines
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
ZA892517B (en) * 1988-04-08 1990-12-28 Lilly Co Eli Propanamine derivatives

Also Published As

Publication number Publication date
NO923710D0 (no) 1992-09-24
JPH05201961A (ja) 1993-08-10
EP0534756A3 (en) 1993-06-16
CA2079161C (en) 2004-02-17
SK290892A3 (en) 2000-02-14
FI111250B (fi) 2003-06-30
CA2079162A1 (en) 1993-03-28
JP3256291B2 (ja) 2002-02-12
US5281624A (en) 1994-01-25
DE69203424T2 (de) 1996-01-11
EP0534756A2 (en) 1993-03-31
HUT65375A (en) 1994-05-02
BR1100384A (pt) 1999-08-31
CN1071416A (zh) 1993-04-28
TW249225B (ko) 1995-06-11
MY108304A (en) 1996-09-30
FI924305A (fi) 1993-03-28
CZ281817B6 (cs) 1997-02-12
SK280480B6 (sk) 2000-02-14
RU2057120C1 (ru) 1996-03-27
ATE124934T1 (de) 1995-07-15
IL103277A0 (en) 1993-02-21
NO178109B (no) 1995-10-16
FI924305A0 (fi) 1992-09-25
JPH05238996A (ja) 1993-09-17
HU9203051D0 (en) 1992-12-28
NO923710L (no) 1993-03-29
MX9205433A (es) 1993-03-01
CA2079161A1 (en) 1993-03-28
IL103277A (en) 1997-11-20
AU655075B2 (en) 1994-12-01
CZ290892A3 (en) 1993-04-14
AU2537092A (en) 1993-04-01
YU87192A (sh) 1995-10-24
KR100221180B1 (ko) 1999-09-15
ZA927240B (en) 1994-03-22
DE69203424D1 (de) 1995-08-17
NO178109C (no) 1996-01-24
BR9203743A (pt) 1993-04-20
NZ244460A (en) 1994-10-26
HU215519B (hu) 1999-01-28
CN1033580C (zh) 1996-12-18

Similar Documents

Publication Publication Date Title
KR930005972A (ko) N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민
KR890003720A (ko) 벤조티아졸 및 그를 유효성분으로 함유하는 항류머티스제
ES2077948T3 (es) Preparacion para el cuidado externo de la piel.
KR910011896A (ko) 신규한 글리코펩티드 유도체
KR890015742A (ko) 이병치료용 국소 제제
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR890007730A (ko) 허혈성 심질환 치료제
KR960006915A (ko) 췌장염의 치료 조성물
KR960007592A (ko) 신규한 피롤로카바졸
ATE284697T1 (de) Pharmazeutische zubereitung auf der basis von rhamnolipid gegen dermatologische erkrankungen
KR930017885A (ko) 항종양 조성물 및 종양의 치료방법
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
KR880002822A (ko) 뇌허혈증 예방 치료제
DK178188A (da) Antivirusmiddel
DE68929321D1 (de) Therapeutische Anwendungen von 2',5'-Oligoadenylat-Derivaten
KR880007494A (ko) 5-아릴-3h-1,2,4-트리아졸-3-온 및 진경제로서의 그들의 용도
KR920703050A (ko) 골형성 촉진제
ES2059348T3 (es) Composicion farmaceutica para el tratamiento de cataratas.
MX9206930A (es) Nuevos compuestos
ES2096099T3 (es) Perhidro-1h-pirido(1,2,a)pirazinas 2-sustituidas neurolepticas.
KR910000645A (ko) 개선된 경련치료제
DK0378146T3 (da) Polyamin-derivater som antineoplastiske midler
KR890001540A (ko) 심부전증 치료제
KR910000638A (ko) 피롤카르복시산 유도체
FR2430230A1 (fr) Medicaments a base de derives de l'acide anthranilique

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030417

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee